Industry News

Pharmaceutical Industry News

In another round of Big Pharma…

May 27th, 2026|Fierce Pharma|

In another round of Big Pharma layoffs in New Jersey, Johnson & Johnson is dismissing 56 employees at its corporate headquarters in New Brunswick. The layoffs are part of the company's effort to separate its

With honor comes scrutiny….

May 27th, 2026|Fierce Pharma|

With honor comes scrutiny. Ivonescimab's plenary status means its Harmoni-6 results in first-line non-small cell lung cancer will be put under the microscope and critiqued carefully at the upcoming ASCO 2026 annual meeting.

As regulatory, pricing and policy…

May 27th, 2026|Fierce Pharma|

As regulatory, pricing and policy dynamics whipsaw in the United States, healthcare and life sciences firms are facing enormous pressures to keep profits rising, with those challenges now “becoming more acute by the quarter,” according

Italy’s antitrust agency, the…

May 27th, 2026|Fierce Pharma|

Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over claims it is abusing its market position regarding a test for its multiple sclerosis drug Tysabri (natalizumab).

Eli Lilly has successfully…

May 27th, 2026|Fierce Pharma|

Eli Lilly has successfully challenged Noom’s “A Smaller Dose. A Smarter Start” claim, leading the National Advertising Division (NAD) to recommend the digital health company change or drop the statement.

After a formal dispute resolution…

May 26th, 2026|Fierce Pharma|

After a formal dispute resolution process that followed three prior rejections, the FDA has decided that Outlook's eye drug candidate Lytenava has shown evidence of effectiveness.

Korea’s SK bioscience has signed…

May 26th, 2026|Fierce Pharma|

Korea’s SK bioscience has signed a technology transfer and manufacturing deal with the Colombian government which will allow the South American nation to produce the company’s chickenpox vaccine SKYVaricella.

More than three years after Gilead…

May 26th, 2026|Fierce Pharma|

More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by scoring a green light in the U.S.

Two years after launching its…

May 26th, 2026|Fierce Pharma|

Two years after launching its “More To Parkinson’s” campaign with actor Ryan Reynolds, Acadia Pharmaceuticals is asking Reynolds to suit up once again as it broadens the project.

Niowave has broken ground on a $75…

May 25th, 2026|Fierce Pharma|

Niowave has broken ground on a $75 million facility at its campus in Lansing, Michigan, which will produce Actinium-225. The radioisotope supplier expects the facility to become operational in 2028 and to employ 70 people.

Less than a month after an FDA…

May 22nd, 2026|Fierce Pharma|

Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s CHMP has blessed Etcamah with a positive opinion. The EMA also has signed off on Novo Nordisk's Wegovy